The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/show/NCT00656565




Registration number
NCT00656565
Ethics application status
Date submitted
7/04/2008
Date registered
11/04/2008
Date last updated
6/08/2008

Titles & IDs
Public title
Inspiratory Flow and Volumes in Bronchiectatics
Scientific title
Inspiratory Flow Rates and Volumes in Subjects With Bronchiectasis Using Low and High Resistance Dry Powder Inhaler Devices
Secondary ID [1] 0 0
DPM-OSM-402
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Bronchiectasis 0 0
Condition category
Condition code
Respiratory 0 0 0 0
Other respiratory disorders / diseases

Intervention/exposure
Study type
Observational
Patient registry
Target follow-up duration
Target follow-up type
Description of intervention(s) / exposure
1 - subjects with bronchiectasis

Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
inspiratory flow
Timepoint [1] 0 0
single visit
Secondary outcome [1] 0 0
inspiratory volume
Timepoint [1] 0 0
single visit

Eligibility
Key inclusion criteria
- non-cf bronchiectasis

- aged 18-80 inclusive

- FEV1 greater or equal to 50% predicted and greater or equal to 1L
Minimum age
18 Years
Maximum age
80 Years
Gender
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
- uncontrolled asthma

- CF bronchiectasis

- have any condition for which spirometry measurement would be contraindicated

Study design
Purpose
Duration
Selection
Timing
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
NSW
Recruitment hospital [1] 0 0
Royal Prince Alfred Hospital - Camperdown
Recruitment postcode(s) [1] 0 0
2050 - Camperdown

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
Pharmaxis
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
Adequate administration of drugs via dry powder inhalers is dependent on adequate inspiratory
flow rates and volumes. These vary according to the device being used and its resistance. The
dry powder inhaler device under investigation is a device approved by the Therapeutic Goods
Administration (ARTG no. 196255) for use with dry powder mannitol. Dry powder mannitol is
currently being investigated as a treatment for bronchiectasis. We wish to measure the
inspiratory flow characteristics of both the low and high resistance devices amongst a group
of subjects with bronchiectasis.

We propose that the majority of subjects investigated with varying lung function will achieve
adequate flow during a controlled inspiration.
Trial website
https://clinicaltrials.gov/show/NCT00656565
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries

Summary results
Other publications